Related Experiment Video
Updated: Apr 15, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
When Selectivity Increases Uncertainty: Context-Dependent Pharmacology in Antibody Drug Development
1Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel, USA.
Highly selective antibody therapeutics exhibit context-dependent pharmacology, complicating drug development. Understanding this biological context is crucial for accurate translation, dosing, and combination therapy selection for biologics.
Area of Science:
- Biopharmaceutical development
- Pharmacology
- Immunotherapy
Background:
- Antibody therapeutics are advancing towards greater selectivity and multi-specificity.
- This increasing complexity makes their pharmacological effects highly dependent on the biological context.
- This context dependence introduces new challenges and uncertainties in drug development.
Purpose of the Study:
- To discuss the implications of context-dependent pharmacology in antibody drug development.
- To highlight how this dependence complicates preclinical-to-clinical translation.
- To address challenges in dose optimization and combination therapy selection for antibody drugs.
Main Methods:
- Perspective-based discussion.
- Analysis of current trends in antibody drug development.
- Review of challenges in translating preclinical findings to clinical applications.
Main Results:
- Context-dependent pharmacology complicates preclinical-to-clinical translation of antibody drugs.
- Dose optimization and selection of rational combination therapies are challenging due to biological context.
- Failure to recognize context dependence limits the therapeutic potential of selective biologics.
Conclusions:
- Recognizing and addressing context-dependent pharmacology is essential for antibody therapeutics.
- A predictive, mechanism-informed paradigm is needed for advanced antibody drug development.
- Understanding biological context is key to realizing the full potential of highly selective biologics.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
09:06Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition
Published on: December 23, 2016
Related Concept Videos
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Phase II Conjugation Reactions: Overview
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Pharmacogenomics: Identification of New Drug Targets